MSLE
Satellos Bioscience Inc. Common Stock
NASDAQ · Healthcare · Medical - Pharmaceuticals · CA
$8.97
−1.21%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -79.0%
- EBIT
- -68.1%
- EPS
- -23.1%
- Free cash flow
- -42.3%
- Operating cash flow
- -42.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -27.5%
Three-year CAGR
- Revenue
- —
- EBITDA
- -35.2%
- EBIT
- -36.6%
- Net income
- -27.0%
- EPS
- —
- Free cash flow
- -35.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026